20 June 2016

Kite Pharma Opens T-Cell Therapy Manufacturing Facility

Kite Pharma, Inc today marked the official opening of its new commercial manufacturing facility in El Segundo, California. Over 300 employees, investors and company partners attended the unveiling of the 43,500-square-foot, state-of-the-art plant. The facility has been designed to produce chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates for clinical trials with the capacity to produce up to 5,000 patient therapies per year. Source: Kite Pharma press release 20/6/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).